Arkin Bio Ventures is the biotech venture capital arm of Arkin Capital, based in Herzliya, Israel. It identifies, invests in, and accompanies innovative early- and mid-stage companies with breakthroughs in areas such as immunotherapy, oncology, metabolism, microbiome, CNS, autoimmune and orphan diseases, and drug delivery platforms.
43% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (43% of deals). Average disclosed round size is $71.3M (across 13 rounds with reported amounts).
Portfolio
14
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
2
Team
Pini Orbach
Managing Partner
Adar Makovski-Silverstein
Principal
Avital Adler
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrossbow | Series B | — | Mar 2026 |
 Ambros Therapeutics | Series A | $125M | Dec 2025 |
 Reunion Neuroscience | Series A | $103M | May 2024 |
| HHI-Bio | Series B | $95M | Jan 2024 |
 Entact Bio | Series A | $81M | Dec 2022 |
 Photys | Series A | $75M | Sep 2022 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Keros Therapeutics | Series C | $56M | Mar 2020 |
| PPi Therapeutics | Series B | $19.7M | May 2019 |
 Metabomed | Unknown | $12.5M | Jan 2019 |
 Nocion Therapeutics | Series B | $62M | — |
| BBionyra | Series A | $165M | — |
| NNocion | Series B | $62M | — |
| KKeros | Series B | $23M | — |
Top Co-Investors
Last updated: 7 September 2026